NVCR News and Press, NovoCure Limited From 11/03/20

Novocure (NVCR) has priced $500M of its 0% convertible senior unsecured notes due November 1, 2025 through a private placement.Initial purchasers granted an option to purchase additional $75M of notes.Closing date is November 5. Special interest on the notes, if any,  will be payabl...

Initial conversion price represents a premium of approximately 50% Novocure (NASDAQ:NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced the pricing of $500 million aggregate principal amount of its 0% C...

Novocure (NVCR) to offer $500M of convertible senior notes due 2025, via a private placement. Initial purchasers have an option to purchase up to an additional $75M notes.Net proceeds will be used to further advance the company's clinical and product development programs and to invest in asso...

Novocure (NASDAQ: NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced its intention to offer $500 million aggregate principal amount of Convertible Senior Notes due 2025 (the “notes”). The notes will ...

Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q3 2020 Earnings Call Oct 29, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q3 2020 Earnings Call Transcript

Novocure Ltd (NVCR) Q3 2020 Earnings Conference Call October 29, 2020, 08:00 ET Company Participants Gabrielle Fernandes - Director, IR William Doyle - Executive Chairman Asaf Danziger - President, CEO & Director Ashley Cordova - CFO & VP, IR Ely Benaim - Chief Medical Officer Uri Wei...

The following slide deck was published by NovoCure Limited in conjunction with their 2020 Q3 earnings call. For further details see: NovoCure Limited 2020 Q3 - Results - Earnings Call Presentation

Novocure (NVCR) has entered into a strategic alliance with the NYU Grossman School of Medicine’s Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. Novocure’s Tumor Treating Fields are elec...

NovoCure (NVCR): Q3 GAAP EPS of $0.09 beats by $0.05.Revenue of $132.66M (+44.1% Y/Y) beats by $12.64M.Gross margin of 79% compared to 75% for Q3 2019.Active patients at period end 3.36M, +22% Y/Y; Prescriptions received 1.37M, +4% Y/Y.Press Release For further details see: NovoCur...

Quarterly net revenues of $132.7 million, representing 44 percent growth versus the third quarter 2019 and 14 percent growth versus the second quarter 2020 Quarterly net income of $9.3 million with $0.09 in earnings per share Novocure (NASDAQ: NVCR) today reported fi...